Universal Biosensors, Inc. ARBN 121 559 993

1 Corporate Avenue Rowville Victoria 3178 Australia

Telephone +61 3 9213 9000 Facsimile +61 3 9213 9099 Email info@universalbiosensors.com www.universalbiosensors.com



14 April 2021

UBI signs Chilean distribution deal.

Universal Biosensors, Inc. (ASX:UBI) is pleased to announce that it has entered into a non-exclusive Distribution Agreement with Singularity SpA for the distribution of its wine testing platform device "Sentia" in Chile.

The Distribution Agreement is for a three-year term and contains standard renewal and termination options available to both parties.

John Sharman, CEO of UBI said; "The launch of Sentia into Chile is another positive step in the commercialisation of Sentia globally. Chile is the 8th largest wine producing country in the world and Singularity is part of a leading group with diverse expertise in point-of-use devices with connections across Chile's 200,000 hectares of vineyards. The deal includes an initial commitment to purchase Sentia devices and strips which will be delivered over the course of the next few weeks."

Mr Sharman said; "We believe the possibility of Sentia's future testing capability for Glucose, Fructose, Malic Acid and others will add significant value to the winemaking industry. We are negotiating terms with a number of key industry players around the world and look forward to reporting additional distribution partnerships in due course."

For further enquiries please refer to the Sentia website (www.mysentia.com).

End

Enquiries: John Sharman Chief Executive Officer +61 (0) 414 440 680

Announcement authorised by the Board of Directors of Universal Biosensors, Inc.



About Universal Biosensors

Universal Biosensors, founded in 2001, specialises in the design and development of electrochemical cells (strips) used in conjunction with point of use devices that are used in various industries such as healthcare (point of care), wine, food, and agriculture. Our wine testing platform Sentia is UBI's new product which is being launched globally. For additional information regarding Universal Biosensors, Inc., refer to: http://www.universalbiosensors.com.

About Singularity SpA

The company is part of a diversified group with a focus on the Chilean biotechnology industry. Its solutions cover diagnostics, quality control, basic and applied research. The group seeks to distribute high quality products in the Chilean market, particularly in the area of rapid tests and esoteric clinical chemistry reagents. Its commitment is to find the best tests and brands worldwide and launch them in Chile.

Forward-Looking Statements

The statements contained in this release that are not purely historical are forward-looking statements within the meaning of the US Securities Exchange Act of 1934. Forward-looking statements in this release include statements regarding our expectations, beliefs, hopes, intentions or strategies. All forward-looking statements included in this release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. Our actual results could differ materially from our current expectations. We cannot assure you when, if at all, the proposals outlined in this release will occur, and the terms of any such proposal are subject to change. Factors that could cause or contribute to such differences include, but are not limited to, factors and risks disclosed from time to time in reports filed with the SEC.